BASEL, SWITZERLAND--(MARKET WIRE)--Sep 14, 2007 -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI) including diabetic foot infections. The regulatory dossier was submitted by Basilea’s license partner Janssen-Ortho, Inc., a Johnson & Johnson company.
